New directions in the treatment of systemic lupus erythematosus.
OBJECTIVE
The aim of this review is to provide an up-to-date overview of treatment approaches for systemic lupus erythematosus (SLE), highlighting the multiplicity and heterogeneity of clinical symptoms that underlie therapeutic decisions. Discussion will focus on the spectrum of currently available therapies, their mechanisms and associated side-effects. Finally, recent developments with biologic treatments including rituximab, epratuzumab, tumor necrosis factor (TNF) inhibitors, and belimumab, will be discussed.


METHODS
A MEDLINE literature search for 'systemic lupus erythematosus' and 'damage' and 'treatment' was undertaken for 1996-2008. Secondary citations were obtained from selected manuscripts. Individual case studies were excluded.


RESULTS
SLE is an autoimmune disease involving multiple organ systems, a clinical pattern of flares and remissions, and the presence of anti-nuclear autoantibodies. Whereas early symptoms most frequently involve the skin and joints, disease morbidity and mortality are usually associated with cardiovascular events and damage to major organs, particularly the kidneys. Many of the current therapeutic options are considered to be inadequate because of toxicities, accrual of organ damage, and insufficient control of the underlying disease pathology. Improved understanding of SLE pathogenesis and immunology has led to the identification of new treatment targets. Current interest is mainly focused on the targeted immunosuppressive actions provided by biologic therapy. Although the potential long-term beneficial or harmful effects of the new molecular treatments are unclear, their precise molecular targeting may reveal key relationships within the immune system and advance the cause of individualized molecular medicine.


CONCLUSIONS
Biologic compounds that target specific immunologic mechanisms offer a new paradigm in the treatment of SLE, one that may, at best, reverse the course of the disease and, at the very least, might provide some new alternatives to reduce symptoms and limit tissue damage without undue contribution to overall morbidity and mortality.
UCSD School of Medicine, La Jolla, CA, USA. kkalunian@ucsd.edu
Kenneth
K
Kalunian
Joan T
JT
Merrill
D000486:Allergy and Immunology / Q000639:trends; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D050197:Atherosclerosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D001778:Blood Coagulation Disorders / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D015897:Comorbidity; D005767:Gastrointestinal Diseases / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D008181:Lupus Nephritis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D020945:Lupus Vasculitis, Central Nervous System / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D009140:Musculoskeletal Diseases / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D057285:Precision Medicine / Q000379:methods / Q000639:trends; D012871:Skin Diseases / Q000453:epidemiology / Q000209:etiology / Q000628:therapy
D000911:Antibodies, Monoclonal